Hiroyuki Okuzawa Director, Senior Executive Officer, Head of Corporate Planning & Management Division, CFO Wataru Takasaki Executive Officer, Head of R&D Division & Vice President of Precision Medicine Function PLAY LIST from the beginning FY2022 Q1 Financial Results Presentation Forward-Looking Statements 1. FY2022 Q1 Financial Results Overview of FY2022 Q1 Results Revenue Core Operating Profit Profit Attributable to Owners of the Company Revenue: Business Units (incl. Forex Impact) Revenue: Major Products in Japan 2. Business Update ENHERTU(R) Revenue ENHERTU(R) Performance in Each Region (US, EU) ENHERTU(R) Performance in Each Region (Japan, ASCA) Initiatives Related to Profit Growth for Current Business and Products 3. R&D Update 3ADC Update ENHERTU(R) DESTINY-Breast04 study ENHERTU(R) DESTINY-Breast04 dataASCO 2022 Highlights (Plenary Session)(1) ENHERTU(R) DESTINY-Breast04 dataASCO 2022 Highlights (Plenary Session)(2) ENHERTU(R) Development of HER2 low breast cancer ENHERTU(R) DESTINY-Breast06/08 studies ENHERTU(R) DESTINY-Breast03 safety data update ASCO 2022 Highlights ENHERTU(R) FY2022 approval status Dato-DXd BEGONIA study interim data ESMO BC 2022 Highlights Dato-DXd New clinical study HER3-DXd Breast cancer Ph1/2 study data ASCO 2022 Highlights HER3-DXd NSCLC Ph1 study cohort 2 data ASCO 2022 Highlights Alpha Update DS-7300 ES-SCLC Ph2 study Development update DS-6000 Ovarian cancer/renal cell carcinoma Ph1 data ASCO 2022 Highlights DXd-ADC Technology Grand prize for 6th Bioindustry awards Quizartinib QuANTUM-First study data EHA 2022 Highlights (Presidential Symposiu) DS-5670 Current development status (1) DS-5670 Current development status (2) DS-2325(KLK5 inhibitor)New clinical study News Flow FY2022 Future News Flow 4. Appendix Major R&D Milestones (3ADCs) Major R&D Milestones (Alpha) Major R&D Pipeline: 3ADCs Major R&D Pipeline: Alpha Contact address regarding this material Q&A Q&A 1 Q&A 2 Q&A 3 Q&A 4 Q&A 5 Q&A 6 Back Next